Get the Stockscreener App
14.91
0.73%
-0.11
Oculis Holding Ag stock is traded at $14.91, with a volume of 33,232.
It is down -0.73% in the last 24 hours and up +6.27% over the past month.
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
See More
Previous Close:
$15.02
Open:
$15.01
24h Volume:
33,232
Relative Volume:
0.68
Market Cap:
$622.42M
Revenue:
-
Net Income/Loss:
$-75.28M
P/E Ratio:
-10.50
EPS:
-1.42
Net Cash Flow:
$-57.45M
1W Performance:
+1.29%
1M Performance:
+6.27%
6M Performance:
+24.35%
1Y Performance:
+55.15%
1-Day Range:
$14.61
$15.06
1-Week Range:
$14.00
$15.43
52-Week Range:
$9.60
$18.00
Oculis Holding Ag Stock (OCS) Company Profile
Compare OCS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| OCS | 14.91 | 622.42M | 0 | -75.28M | -57.45M | -1.42 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-14-23 | Initiated | BofA Securities | Buy |
| Jun-12-23 | Initiated | H.C. Wainwright | Buy |
| Jun-08-23 | Initiated | Robert W. Baird | Outperform |
| May-10-23 | Initiated | Pareto | Buy |
| Apr-28-23 | Initiated | Wedbush | Outperform |
Oculis Holding Ag Stock (OCS) Latest News
Oculis (NASDAQ:OCS) Shares Up 3.8%Here's Why - MarketBeat
(OCS) Investment Analysis - Stock Traders Daily
Is Oculis Holding (OCS) Top Performing European Stock Heading into 2025? - Insider Monkey
Oculis to Present at the Stifel 2024 Healthcare Conference - The Manila Times
Oculis (OCS) to Present at Stifel Healthcare Conference: CFO Fireside Chat Announced | OCS Stock News - StockTitan
10 Top Performing European Stocks Heading into 2025 - Insider Monkey
HC Wainwright Reiterates Buy Rating for Oculis (NASDAQ:OCS) - MarketBeat
Oculis Holding AG Reports Q3 2024 Financial Progress - TipRanks
Oculis Holding’s Financial Struggles Amid Asset Growth - TipRanks
Oculis Holding AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Oculis Reports Q3 2024 Financial Results and Provides Company Updates - GlobeNewswire
Oculis birtir uppgjör fyrir þriðja ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins - GlobeNewswire Inc.
Oculis (OCS) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat
Oculis (NASDAQ:OCS) Hits New 12-Month HighWhat's Next? - MarketBeat
Oculis: Lack Of Coverage Only Real Risk For This Solid Company - Seeking Alpha
abrdn plc Sells 279,879 Shares of Oculis Holding AG (NASDAQ:OCS) - MarketBeat
Oculis (NASDAQ:OCS) Sees Strong Trading VolumeHere's Why - MarketBeat
Oculis Holding AG (OCS) Moves 7.9% Higher: Will This Strength Last? - MSN
Oculis Holding AG's (NASDAQ:OCS) largest shareholders are individual investors with 56% ownership, institutions own 39% - Yahoo Finance
Oculis (NASDAQ:OCS) Reaches New 1-Year HighStill a Buy? - MarketBeat
Short Interest in Oculis Holding AG (NASDAQ:OCS) Grows By 133.7% - MarketBeat
Trading (OCS) With Integrated Risk Controls - Stock Traders Daily
Oculis (NASDAQ:OCS) Shares Gap DownHere's Why - MarketBeat
Oculis (NASDAQ:OCS) Shares Gap UpHere's Why - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for Oculis (NASDAQ:OCS) - MarketBeat
Financial Comparison: Oculis (NASDAQ:OCS) and Terns Pharmaceuticals (NASDAQ:TERN) - Defense World
Oculis (NASDAQ:OCS) Reaches New 52-Week HighTime to Buy? - MarketBeat
Oculis Holding AG's (NASDAQ:OCS) market cap touched US$586m last week, benefiting both individual investors who own 55% as well as institutions - Simply Wall St
Oculis accelerates patient enrollment for both Phase 3 DIAMOND trials - TipRanks
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees - StockTitan
Oculis (NASDAQ:OCS) Trading Up 4.8%Here's What Happened - MarketBeat
Oculis Accelerates Enrollment in both DIAMOND Phase 3 - GlobeNewswire
OCSOculis Holding AG Ordinary shares Latest Stock News & Market Updates - StockTitan
Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema - GlobeNewswire
Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024 - StockTitan
Oculis (NASDAQ:OCS) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Belite Delights Investors, Soleno, ADMA, Harrow Deliver Triple-digit Gains, Keep An Eye On Oculis - RTTNews
Oculis (NASDAQ:OCS) Hits New 52-Week High – Here’s What Happened - Defense World
Oculis (NASDAQ:OCS) Hits New 52-Week HighWhat's Next? - MarketBeat
Oculis Holding AG (OCS) Surges 8.2%: Is This an Indication of Further Gains? - Yahoo Finance
Objective long/short (OCS) Report - Stock Traders Daily
Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer - Vision Monday
Oculis Holding Ag Stock (OCS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):